Active Ingredient: FUROSEMIDE
In patients with CKD, furosemide is associated with significant QT prolongation. Notably, this effect appears to be independent of serum potassium and calcium levels, suggesting an inherent impact on cardiac conduction. Additive QTc prolongation is observed when combined with drugs like venlafaxine or spironolactone. Electrolyte monitoring alone may be insufficient to assess cardiac risk. However, according to this paper https://doi.org/10.2215/CJN.12991216, furosemide appears to prolong the QT interval by 3ms
https://doi.org/10.1038/hr.2015.30, https://doi.org/10.2215/CJN.12991216